Franklin Genomic AdvancementHELXETF
13F holders, Q2 2026 (June 30)6holders
1new positions
1sold out
1famous investor
$39.97avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($1.5M), Citadel Advisors ($1.4M) and LPL Financial LLC ($616K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1.5M |
| Exits | 1 | $3K |
All 13F filers, Q1 2026 → Q2 2026: 47,774 shares bought and 4,252 shares sold, net +43,522 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Susquehanna International Group, LLP | 0.00% | New | 38,272 | $1.5M |
| Citadel Advisors | 0.00% | Reduce -10.0% | 33,800 | $1.4M |
| LPL Financial LLC | 0.00% | Add +129.7% | 15,404 | $616K |
| Osaic Holdings, Inc. | 0.00% | Add +34.4% | 3,142 | $126K |
| Franklin Resources Inc. | 0.00% | No change | 2,675 | $107K |
| Harbour Investments, Inc. | 0.00% | Reduce -23.9% | 1,255 | $50K |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.